Literature DB >> 7273326

Formation of urothelial and hepatic DNA adducts from carcinogen 2-naphthylamine.

F F Kadlubar, J F Anson, K L Dooley, F A Beland.   

Abstract

The carcinogen, 2-naphthylamine (2-NA), induces tumor formation in the urinary bladder but not the liver of several species, including humans and dogs. Since its proximate carcinogenic metabolite, N-hydroxy-2-NA, was known to react directly with DNA in vitro to give specific carcinogen-base adducts, we investigated the in vivo formation and persistence of (2-NA)-DNA adducts in the bladder and liver and attempted to determine whether or not these lesions correlated with tissue susceptibility. Male beagle dogs were administered [3H]2-NA and sacrificed after 2 or 7 days. The DNA was isolated from the liver and urothelium and hydrolyzed enzymatically. The (2-NA)-deoxyribonucleoside adducts, which were quantitated by high pressure liquid chromatographic analysis, were the same as those found in vitro, namely 1-(deoxyguanosin-N2-yl)-2-NA, 1-(deoxyadenosin-N6-yl)-2-NA, and an imidazole ring-opened derivative of N-(deoxyguanosin-8-yl)-2-NA. The major difference detected between target and non-target tissues was in the total level of binding to DNA, which was 4-fold higher in the urothelium at 2 days and 8-fold higher at 7 days after 2-NA dosing. Analysis of specific adducts suggested that this difference may be due to the relative persistence of the C-8-guanine adduct in the urothelium as compared to the liver. Similar experiments with the non-carcinogen, 1-naphthylamine, failed to reveal binding in urothelial DNA and indicated a 20-fold lower binding level in hepatic DNA. Evidence for binding of 2-NA to glycogen is also presented and problems associated with measuring total radioactivity in glycogen-contaminated DNA fractions are discussed. The data obtained in this study, through from a necessarily limited number of animals, are consistent with the hypothesis that the formation and persistence of DNA-carcinogen adducts may be important in the initiation of the neoplastic process.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7273326     DOI: 10.1093/carcin/2.5.467

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  8 in total

Review 1.  Nucleic acid adducts of chemical carcinogens and mutagens.

Authors:  K Hemminki
Journal:  Arch Toxicol       Date:  1983-04       Impact factor: 5.153

2.  Characterization of nitrogen mustard formamidopyrimidine adduct formation of bis(2-chloroethyl)ethylamine with calf thymus DNA and a human mammary cancer cell line.

Authors:  Francesca Gruppi; Leila Hejazi; Plamen P Christov; Sesha Krishnamachari; Robert J Turesky; Carmelo J Rizzo
Journal:  Chem Res Toxicol       Date:  2015-09-01       Impact factor: 3.739

3.  Aminofluorene-DNA adduct formation in Salmonella typhimurium exposed to the carcinogen N-hydroxy-2-acetylaminofluorene.

Authors:  D T Beranek; G L White; R H Heflich; F A Beland
Journal:  Proc Natl Acad Sci U S A       Date:  1982-09       Impact factor: 11.205

4.  Chemical and biochemical dosimetry of exposure to genotoxic chemicals.

Authors:  G N Wogan; N J Gorelick
Journal:  Environ Health Perspect       Date:  1985-10       Impact factor: 9.031

5.  Arylamine-DNA adducts in vitro and in vivo: their role in bacterial mutagenesis and urinary bladder carcinogenesis.

Authors:  F A Beland; D T Beranek; K L Dooley; R H Heflich; F F Kadlubar
Journal:  Environ Health Perspect       Date:  1983-03       Impact factor: 9.031

6.  Formation and persistence of arylamine DNA adducts in vivo.

Authors:  F A Beland; F F Kadlubar
Journal:  Environ Health Perspect       Date:  1985-10       Impact factor: 9.031

7.  Lifetime carcinogenicity study of 1- and 2-naphthylamine in dogs.

Authors:  I F Purchase; A E Kalinowski; J Ishmael; J Wilson; C W Gore; I S Chart
Journal:  Br J Cancer       Date:  1981-12       Impact factor: 7.640

8.  Oxidative DNA damage induced by a metabolite of 2-naphthylamine, a smoking-related bladder carcinogen.

Authors:  Shiho Ohnishi; Mariko Murata; Shosuke Kawanishi
Journal:  Jpn J Cancer Res       Date:  2002-07
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.